Dan Zabrowski - 23 Aug 2023 Form 4 Insider Report for Apexigen, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 23 Aug 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 25 Aug 2023, 19:42:15 UTC
Prior SEC filing: 03 Oct 2022
Next SEC filing: 12 Aug 2024
Source filing: View source filing
Reporting owner signature: /s/ Francis Sarena, by power of attorney

Key filing fact

Dan Zabrowski filed Form 4 for Apexigen, Inc. on 25 Aug 2023.

Key facts

This page summarizes Dan Zabrowski's Form 4 filing for Apexigen, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 25 Aug 2023, 19:42.

Change

Previous filing in this sequence was filed on 03 Oct 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

APGN transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -100,000
Change %: -100%
Price
Shares after: 0
Date: 23 Aug 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 100,000
Exercise price: $2.65
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Dan Zabrowski is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 1 footnote

Footnote F1

The shares subject to the option vest in three equal annual installments beginning on July 29, 2023. Pursuant to an Agreement and Plan of Merger, dated as of May 23, 2023, by and among the Issuer, Pyxis Oncology, Inc. ("Pyxis"), and Ascent Merger Sub Corp., at the effective time of the merger (the "Effective Time"), the option was assumed by Pyxis and converted into an option to purchase 17,250 shares of Pyxis common stock at an exercise price of $15.37 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time.